Literature DB >> 3337052

Marrow fibrosis and multiple myeloma.

R L Krzyzaniak1, D H Buss, M R Cooper, H B Wells.   

Abstract

A retrospective review of pretreatment bone marrow material from 297 patients diagnosed and treated for multiple myeloma (MM) at a single institution during a 22-year period (1961-1982) was performed in order to assess the frequency and significance of associated simple marrow fibrosis (SMF). The presence of SMF was suspected in the hematoxylin and eosin-stained sections in 48 of the 297 cases and was confirmed by reticulin stains in 26 (8.8%) cases, with seven of these also showing collagen on trichrome stain. However, the literature on MM documents little recognition of this association. SMF is often responsible for inadequate marrow aspirates yielding spurious or inconclusive results. Thus, bone marrow trephine biopsies may be required to histologically confirm the diagnosis of MM when there is concurrent SMF.

Entities:  

Mesh:

Year:  1988        PMID: 3337052     DOI: 10.1093/ajcp/89.1.63

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  C Schmid; P G Isaacson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

2.  Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies.

Authors:  A Pich; L Chiusa; F Marmont; N Cappello; R Navone
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; A Castello; A Coci; U Magrini; E Ascari
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

4.  Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy.

Authors:  M C Kuo; L Y Shih
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

5.  Plasma cell leukemia with myelofibrosis.

Authors:  T Murayama; T Matsui; Y Hayashi; T Taniguchi; M Ito; T Natazuka; S Imoto; N Iwata; T Isobe; H Ito
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

6.  Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report.

Authors:  George Tsirakis; Peggy Kanellou; Maria Kaparou; Andrew Passam; Amalia Zampoulaki; Kostas Stylianou; Michael G Alexandrakis
Journal:  ISRN Hematol       Date:  2011-05-19

7.  The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Authors:  Barry Paul; Yue Zhao; Gavin Loitsch; Daniel Feinberg; Parker Mathews; Ian Barak; Megan Dupuis; Zhiguo Li; Lindsay Rein; Endi Wang; Yubin Kang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.